De Brauw advised underwriters on secondary offering of shares in NewAmsterdam Pharma. NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients...
NewAmsterdam Pharma’s USD181 Million Secondary Offering
Cerence’s $190 Million Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering. Cerence Inc. (NASDAQ: CRNC) announced the pricing of $190.0 million aggregate principal amount of 1.50% convertible...
Oculis Holding’s $40.25 Million Debut Equity Offering
Davis Polk advised BofA Securities, Inc., SVB Securities LLC on the offering. Cooley LLP represented Oculis Holding in the offering. Vischer AG advised Oculis Holding for...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Abivax’s EUR 130 Million Cross-Over Financing
Gide advised financial advisers SVB Securities, LifeSci Capital and Bryan and Garnier & Co. The banks were also advised by Cooley LLP on aspects of US...
Arcus Biosciences’ $200 Million At-the-Market Offering
Gunderson Dettmer advised sales agents Goldman Sachs & Co. LLC and SVB Securities on the deal. Goldman Sachs & Co. LLC and SVB Securities acted as sales agents in...
Travere Therapeutics’ $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters. Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of...
Structure Therapeutics’ $185.3 Million IPO
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
CureVac’s $250 Million Common Shares Offering
NautaDutilh and Davis Polk advised CureVac on the offering, while Latham & Watkins advised the underwriters involved. CureVac N.V. announced the pricing of 27,027,028 common shares...
Roivant Sciences’ $230 Million Common Shares Offering
Davis Polk & Wardwell represented Roivant Sciences, while Latham & Watkins represented the underwriters in the offering. Roivant Sciences (Nasdaq: ROIV) has announced its $230 million...
Prometheus Biosciences’ $500 Million Shares Offering
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...